Table 3.
Overview of the medication applied in the TAK cohort
| Treatment | At diagnosis | Accumulated | At last visit | |||
|---|---|---|---|---|---|---|
| cohort | Early | Late | Early | Late | Early | Late |
| Prednisolone p.o, n (%) | 14 (70) | 59 (86) | 24 (100) | 63 (91) | 16 (67) | 53 (77) |
| Metylprednisone i.v. n (%)a | 0 | 17 (25)** | 2 (8) | 22 (32)** | 0 | 1 (1.4) |
| Any DMARDs, n (%) | 1 (4) | 35 (51)*** | 13 (54) | 61 (88)*** | 7 (29) | 51 (74)*** |
| Methotrexate | 1 (4) | 28 (41)*** | 11 (46) | 55 (80)*** | 5 (21) | 42 (61)*** |
| Azathioprine | 0 | 7 (10) | 7 (29) | 18 (26) | 2 (8) | 8 (12) |
| Mycophenelate mofetil | 0 | 1 (4) | 3 (4) | 0 | 1 (1.4) | |
| Cyclophosphamideb | 2 (8) | 6 (9) | 4 (17) | 7 (15) | 0 | 0 |
| Any biologic, n (%) | 0 | 0 | 3 (13) | 30 (44)* | 3 (13) | 23 (33)* |
| Infliximab | 0 | 0 | 2 (8) | 29 (42)** | 1 (4) | 16 (23)* |
| Etanercept | 0 | 0 | 2 (8) | 3 (4) | 1 (4) | 1 (1.4) |
| Adalimumab | 0 | 0 | 1 (4) | 3 (4) | 1 (4) | 3 (4) |
| Tocilizumab | 0 | 0 | 1 (4) | 5 (7) | 0 | 3 (4) |
| Other medication, n (%) | ||||||
| Acetylsalicylic acid | 2 (8) | 32 (46)** | 16 (67) | 47 (68) | 13 (57) | 41 (59) |
| Statin | 1 (4) | 16 (23) | 16 (67) | 34 (49) | 13 (57) | 32 (46) |
The early cohort (n = 24) included all patients diagnosed before year 2000, and the late cohort (n = 63) included patients diagnosed between 2000 and 2012. p.o. oral, i.v. intravenous. aUsually as 1000 mg daily for 3 consecutive days. bGiven as i.v. treatment 6 × 15 mg/kg. Significant differences between the cohorts are indicated: *p < 0.05, **p < 0.01, ***p < 0.001